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 In this issue of  Kidney International , 
Goraya  et al. 1 report that reduction in 
acid load to the body by increased intake 
of alkali in the form of either a diet rich 
in fruits and vegetables or oral sodium 
bicarbonate reduces urinary markers of 
kidney damage in patients with stage 2 
chronic kidney disease (CKD). 1 Th e arti-
cle is a natural extension of the authors ’ 
previous works to establish a relationship 
between metabolic acidosis and progres-
sion of CKD. 2 In this Commentary we 
will address three issues: (1) Is alkali 
therapy eff ective in slowing loss of kidney 
function in CKD? (2) What are the 
potential mechanisms? (3) How does the 
article by Goraya  et al. 1 clarify the fi rst 
two questions? 
 A number of studies in animals have 
shown benefi cial eff ects of alkali supple-
mentation in slowing the progression of 
kidney disease, 3 although these fi ndings 
have not been universal. Two studies in 
particular, both from the same authors, 
showed the opposite fi nding, namely, that 
ammonium chloride was benefi cial. How-
ever, in the latter study, the protective 
eff ect of ammonium chloride was observed 
with a high-phosphorus diet that resulted 
in very high serum phosphorus. 4 
 Clinically, the association between met-
abolic acidosis and CKD progression has 
been suggested by observational studies 
and by several small and nonrandomized 
studies in which alkali supplementation 
slowed the loss of kidney function in CKD 
patients. 3 More recently, however, two 
small randomized clinical trials have dem-
onstrated a benefi cial eff ect of oral alkali 
supplementation in the progression of 
kidney disease. Th e fi rst one was a ran-
domized trial of oral sodium bicarbonate 
supplementation vs. standard care per-
formed in 134 adults with stage 4 CKD 
(glomerular fi ltration rate 15 – 30  ml / min 
per 1.73  m 2 ) and serum bicarbonate con-
centrations between 16 and 20  mmol / l. 5 
At the end of two years of follow-up, 22 
patients in the control group and four in 
the bicarbonate group progressed to dial-
ysis (6.5 vs. 33 % , respectively). Among 
patients who did not require initiation of 
dialysis, those in the bicarbonate group 
were signifi cantly less likely to experience 
rapid progression defined by a loss of 
glomerular fi ltration rate of more than 
3  ml / min per 1.73  m 2 per year (9 vs. 45 % ). 5 
Although the end points were clinically 
meaningful and their diff erences were sta-
tistically signifi cant, this study lacked a 
placebo control group, and it was not 
blinded. Th e second study was a prospec-
tive, randomized, placebo-controlled, 
blinded intervention of daily oral NaHCO 3 
vs. NaCl or placebo in subjects with mac-
roalbuminuric hypertensive nephropathy 
and stage 2 CKD. 2 Aft er 5 years, the rate 
of estimated glomerular filtration rate 
(eGFR) decline was slower and eGFR was 
higher in patients given NaHCO 3 than in 
those given placebo or NaCl. 2 Th e main 
limitation of the study was the relatively 
small number of patients ( n  =  40 per 
group). Th e above data support the incor-
poration of oral alkali supplementation as 
part of the routine clinical care of patients 
with CKD with a low serum bicarbonate 
concentration or in the low range of nor-
mal. Despite the fact that patients in the 
study by Mahajan  et al. 2 had baseline 
serum bicarbonate of 26  mmol / l, the ben-
efi ts of oral alkali supplements in patients 
with  ‘ normal ’ serum bicarbonate remain 
to be clearly demonstrated in a larger 
number of subjects. If alkali therapy is 
indeed eff ective, what is the mediating 
mechanism or mechanisms? Th ere are 
several hypotheses. One possible mecha-
nism is that the acidic pH itself increases 
production of reactive oxygen species, 
which in turn will cause renal damage 
through oxidative injury. Another mecha-
nism is acidosis-induced upregulation of 
the endothelin gene, leading to vasocon-
striction and fi brosis. 2 Another theory is 
that acidic pH increases ammonia pro-
duction in the proximal tubule, and high 
ammonia causes injury by activating the 
alternative pathway of complement. 6 
Th ere is a substantial amount of evidence 
that ammonia can activate C3. C3 nor-
mally forms an intramolecular thioester 
bond by reaction of the SH group of 
cysteine-988 with the amide nitrogen of 
glutamine-991, and the creation of this 
thioester bond apparently confers stabil-
ity. Th e reaction occurs with the release of 
ammonia and formation of a thioester 
bond and a ring structure consisting of 
four amino acids (cysteine, glycine, gluta-
mic acid, and glutamine). 7 In an environ-
ment with high ammonia concentration, 
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the thioester bond is attacked by ammo-
nia, which is quite nucleophilic. As the 
bond is broken, ammonia is inserted into 
glutamine, forming an amide bond. 7 Th e 
resulting C3 without a thioester bond 
undergoes conformational changes and 
acquires the enzyme activity of C3b, which 
can convert C3 to C3a and C3b; this is the 
start of the activation of the alternative 
complement pathway. If an increased load 
of ammonia per kidney mass is responsi-
ble for activation of complement and 
therefore progression of kidney injury, 
one would have expected that other con-
ditions characterized by high urinary 
ammonia would also accelerate renal dis-
ease. In fact, associations of CKD and 
chronic hypokalemia (as with surrepti-
tious diuretic use, eating disorders, laxa-
tive abuse, or primary aldosteronism) 
have been observed for many years, and 
hypokalemic nephropathy is an entity 
clearly described, although not widely 
recognized in clinical nephrology. 
 Th e current study by Goraya  et al. 1 tests 
the hypothesis that, as daily acid load is 
primarily dependent on the type of food 
ingested, increasing the daily intake of 
fruits and vegetables might have eff ects 
similar to those of alkali therapy in pre-
serving renal function. Indeed, the study 
showed similar eff ects of oral NaHCO 3 
and a diet rich in fruits and vegetables 
(calculated to reduce acid load by 50 % ) in 
patients with stage 2 CKD, although no 
eff ects were noted in stage 1 CKD patients. 
A major problem with this study, however, 
is the use of indirect markers (urinary 
excretion of albumin,  N -acetyl-  - d -
 glucosaminidase, and transforming 
growth factor-  ) and not changes in 
glomerular filtration rate as primary 
outcome, and therefore the conclusions 
should be accepted with caution. As we do 
not know the actual mechanisms of how 
alkali supplementation slows down renal 
injury, the eff ect of the intervention on 
these markers may turn out to be irrele-
vant in terms of the real outcome: preser-
vation of renal function. For example, 
there is no supportive evidence that 
 N -acetyl-  - d - glucosaminidase has any 
direct adverse eff ect on the kidney. Inter-
estingly, however, fi colin can be activated 
by binding to  N -acetyl-  - d -glucosamine, 
which is usually found on the cell mem-
brane of microorganisms but can be found 
on human tissues, especially when they 
are damaged. It is tempting to speculate 
that increased  N -acetyl-  - d -glucosami-
nidase represents availability of  N -acetyl-
  - d -glucosamine on renal tissue, which 
can activate the lectin-mediated comple-
ment system. Ficolin, like mannose-bind-
ing lectin, can activate the complement 
system through its action on C4 and C2, 
once it binds a suitable ligand such as 
 N -acetyl-  - d -glucosamine. 8 Moreover, a 
diet rich in fruits and vegetables could 
potentially slow down renal disease pro-
gression by several eff ects independent of 
decreasing acid load, for example, relative 
increase of potassium over sodium intake, 
decreased phosphorus load, and increased 
intake of fi bers, antioxidants, vitamins, and 
chemicals such as sulforaphane ( Figure 1 ). 
Th e latter compound is known to activate 
nuclear factor (erythroid-derived 2)-like 2 
(Nrf2), and other compounds that activate 
Nrf2, such as bardo xolone, have been 
shown to improve renal function. 9 Goraya 
 et al. 1 recognize that a signifi cant eff ect of 
the fruit-and-vegetable-rich diet is decreas-
ing blood pressure, a factor known to slow 
loss of kidney function. Regardless of 
mechanisms, a fruit-and-vegetable-rich 
diet has so many potential benefi cial eff ects 
that it could be easily accepted for imple-
mentation. Th is study is also important 
because it illustrates a very simple and safe 
way to treat metabolic acidosis, an inter-
vention to slow CKD progression that has 
not received enough attention. 
 Interestingly, use of sodium bicarbonate 
infusion prior to use of intravenous con-
trast media is now widely practiced, but it 
is not known whether some or all the 
above mechanisms are responsible for its 
eff ectiveness, if it is indeed eff ective. 
 Finally, in view of the above discussion, 
it is tempting to speculate that the age-
related decline in renal function is also due 
to the ammonia toxicity that results partly 
from the greater acid load of the modern 
diet in comparison with the Paleolithic 
diet. Sebastian  et al. 10 have argued that so-
called normal values for serum bicarbonate 
vary with the dietary intake of alkali. It is 
likely that the renal production of ammo-
nia on the Paleolithic diet was substantially 
lower than that on the modern diet. Per-
haps, the so-called age-related decline in 
renal function is a result of damage induced 
by ammonia overproduction. 
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 Protecting podocytes: how 
good do we need to be ? 
 Kevin V.  Lemley 1 
 Progression of many glomerular diseases has been firmly tied to a loss 
of podocytes, followed by a deterioration of glomerular architectural 
stability eventuating in segmental, and ultimately global, sclerosis. 
Recent studies have begun to clarify the nature of the autonomous 
(disease-independent) aspects of this process, as well as to explore 
mechanistically the  ‘ unreasonable effectiveness ’ of angiotensin blockade 
in slowing glomerular disease progression. Quantitative monitoring of 
podocyte loss (e.g., to assess therapy) remains a challenge. 
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 Th e fi rst indications of the importance of 
podocyte loss in the progression of kidney 
diseases came from animal models 1 and 
from cross-sectional studies of human 
disease. 2 Th e concept of podocyte  ‘ insuf-
fi ciency, ’ fi rst clearly enunciated by Rennke 
and co-workers, 1 was further developed 
by Kriz and co-workers 3,4 into the current 
canonical model for the development of 
glomerular sclerosis: a loss of podocytes 
leads to  ‘ bare areas ’ of glomerular base-
ment membrane, which in turn lead to 
formation of synechiae to Bowman ’ s cap-
sule and then to segmental and finally 
global glomerular sclerosis. 
 More recently, ingenious animal models 
have been developed in the mouse 5 and 
the rat 6 that allow a much more precise 
titration of the degree of podocyte loss than 
was possible with previous models using 
podocyte toxins such as puromycin or adri-
amycin. Th is has allowed those aspects of 
glomerular disease progression due solely 
to reduced podocyte number to be studied 
in isolation. In some sense, this represents 
the intraglomerular analog of the subtotal 
nephrectomy model  introduced decades 
ago to study the eff ects of reduced nephron 
number on renal disease progression. Also 
analogous to the subtotal nephrectomy 
model is the existence of an apparent 
threshold level of initial podocyte loss nec-
essary for the subsequent development of 
an autonomous phase of podocyte loss. 
 Fukuda and colleagues 7 (this issue) now 
present a meticulous study of the natural 
history of the autonomous progression of 
podocyte loss and consequent glomerular 
sclerosis, and their modulation through 
angiotensin blockade. Th e study is based 
largely on the authors ’ technique of tar-
geting podocytes for killing by diphtheria 
toxin (DT) in a transgenic rat model in 
which the human DT receptor (hDTR) is 
expressed under the control of the 
(human) podocin promoter. 6 Th e rodent 
analog of the hDTR does not bind DT, so 
wild-type rats are naturally resistant to its 
cytotoxic eff ects. Since, under the control 
of the podocin promoter, the hDTR is 
expressed only in podocytes of the trans-
genic rats, it is only these cells that take up 
and are killed by administered DT. Diff er-
ent levels of initial podocyte loss can be 
achieved by varying doses of DT. Other 
rat models (subtotal nephrectomy, puro-
mycin) support the generality of Fukuda 
and colleagues ’ 7 fi ndings in this model. 
 Th e authors estimate glomerular podo-
cyte number by two complementary 
methods: the thick-and-thin-section 
method to determine the number of WT-
1-positive nuclei (podocytes) per unit 
glomerular volume, and the fraction of 
glomerular tuft  staining for GLEPP1, a 
podocyte-expressed protein. In addition, 
the authors use a surrogate indicator for 
urinary podocyte loss — mRNA for the 
podocyte proteins podocin and nephrin 
in the urinary sediment. Th ese more novel 
indicators of progression are correlated 
with the incidence of glomerular sclerosis 
and quantitative proteinuria. 
 Fukuda and colleagues 7 show that a 
process of autonomous progression — based 
on ongoing podocyte loss — follows the ini-
tial loss of a threshold fraction of podocytes 
(greater than about 30 % ) induced by DT. 
Ongoing loss of podocytes  ‘ destabilizes ’ the 
glomerulus, leading to glomerular sclerosis. 
Progression can be prevented by combined 
angiotensin blockade (with enalapril and 
losartan). Interestingly, the eff ect of angi-
otensin blockade on proteinuria is quite 
rapid (presumably reflecting improved 
podocyte function), whereas beneficial 
eff ects on urinary podocyte excretion (as 
reflected in urine podocin mRNA) are 
delayed by 2 weeks. If angiotensin blockade 
is stopped, the several indices of autono-
mous progression recommence. 
 It has long been known that angiotensin 
blockade is  ‘ unreasonably eff ective ’ in pre-
venting progression of many renal diseases. 
So what does this study add to our under-
standing of how angiotensin blockade pre-
vents progression? Th e most signifi cant 
fi nding is that prevention of autonomous 
